No Data
Zhejiang Jingxin Pharmaceutical (002020.SZ): Plans to spend 0.2 billion to -0.4 billion yuan to repurchase company shares.
On January 8, Gelonghui reported that Zhejiang Jingxin Pharmaceutical (002020.SZ) announced that the company would use its own funds to repurchase shares through centralized bidding. The repurchased shares will be used for Stock-based Incentive or employee stock ownership plans. The total amount of the repurchase will not be less than 0.2 billion yuan (inclusive) and not more than 0.4 billion yuan (inclusive), with the repurchase price not exceeding 14.8 yuan per share (inclusive). If calculated based on the upper and lower limits of the total repurchase amount and the upper limit of the repurchase share price, the estimated number of shares to be repurchased is approximately 13.51 million to -27.03 million shares, accounting for about 1.57% to 3.14% of the company's current total equity.
Zhejiang Jingxin Pharmaceutical (002020.SZ): There are currently no plans to enter the Ophthalmology field.
Gelonghui December 26丨 Zhejiang Jingxin Pharmaceutical (002020.SZ) stated on the investor interaction platform that the company has no current plans to enter the Ophthalmology field.
Zhejiang Jingxin Pharmaceutical (SZSE:002020) Sheds 4.2% This Week, as Yearly Returns Fall More in Line With Earnings Growth
Zhejiang Jingxin Pharmaceutical (002020.SZ): Didanosine is a globally unique exclusive variety.
On December 18, Gelonghui reported that Zhejiang Jingxin Pharmaceutical (002020.SZ) stated on an investor interaction platform that the company's Didasini is a globally innovative exclusive variety, and multiple patents are currently under protection.
Zhejiang Jingxin Pharmaceutical (002020.SZ): The company's diadizine is a globally innovative exclusive variety, with multiple patents still under protection.
Glory Financial, December 18 – Zhejiang Jingxin Pharmaceutical (002020.SZ) stated on the investor interaction platform that the company's dadarizine is a globally pioneering exclusive variety, and currently multiple patents are within the protection period.
Zhejiang jingxin pharmaceutical (002020.SZ): The enteric-coated capsules for rehabilitation are currently nearing the end of Phase II clinical trials.
Glemanet December 3rd | zhejiang jingxin pharmaceutical (002020.SZ) stated on the investor interaction platform on December 3rd that the recovery new enteroic capsule is currently in the late stage of phase II clinical trials, and the company will proceed with the phase III clinical trials of this variety as soon as possible after the completion of phase II according to plan.
Zhejiang Jingxin Pharmaceutical (SZSE:002020) Jumps 5.8% This Week, Though Earnings Growth Is Still Tracking Behind Five-year Shareholder Returns
